Synaptogenix announced plans to advance bryostatin-1, its lead candidate, into clinical trials for multiple sclerosis (MS), marking the third neurological disease the small molecule therapy is being developed to potentially treat.
“Multiple sclerosis joins Alzheimer’s disease (“AD”) and Fragile X syndrome as our third indication with potential clinical benefit from Bryostatin-1,” Daniel Alkon, MD, Synaptogenix’s president and chief scientific officer, said in a press release.
“Elimination of synapses in MS patients, like those lost in AD, has not been addressed by currently available drug strategies,” Alkon added. Synapses are the points of near contact between nerve cells where cells transmit chemical and electrical signals to one another.
“Through its [synaptic formation-promoting], restorative mechanisms of action, we believe that Bryostatin-1 is uniquely positioned to target synaptic loss and cognitive dysfunction in MS, and potentially other aspects of the disease such as inflammation and [myelin loss],” he said.Synaptogenix expects to file an investigational new drug application to the U.S. Food and Drug Administration in the coming months, asking for clearance to launch a first trial of bryostatin-1 in people with MS.
“To read this article in its entirety click this link: Bryostatin-1, Molecule to Protect Synapses, May Move Into MS Trials.“